Sangamo Therapeutics

SGMO

Market cap $195M

Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval Isaralgagene civaparvovec showed a favorable safety and tolerability profile Sangamo intends to submit a Biologics License Application (BLA) in 2026 under the Accelerated Approval pathway RICHMOND, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced detailed data from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease.

Sangamo (SGMO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alexander D. Macrae - CEO, President & Director Gregory Davis - Head of Research & Technology Louise Wilkie - Head of Global Corporate Communications & Investor Relations Nathalie Dubois-Stringfellow - Senior VP & Chief Development Officer Prathyusha Duraibabu - Senior VP, CFO & Principal Accounting Officer Conference Call Participants James D Stamos - Jefferies LLC, Research Division Joshua Seth Fleishman - TD Cowen, Research Division Kuan-Hung Lin - Unidentified Company Liu Deng - Barclays Bank PLC, Research Division Luis Santos - Unidentified Company Operator Good afternoon, and welcome to the Sangamo Therapeutics Second Quarter 2025 Teleconference Call.

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.17 per share a year ago.

Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval. First clinical site initiated for Phase 1/2 STAND study in chronic neuropathic pain.

RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on Thursday, August 7, 2025.

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2025 Earnings Conference Call May 12, 2025 6:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Prathyusha Duraibabu - Chief Financial Officer Conference Call Participants Nicole Germino - Truist Luis Santos - H.C. Wainwright Operator Good afternoon and welcome to the Sangamo Therapeutics First Quarter 2025 Teleconference Call.

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.27 per share a year ago.

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results.